shRNA constructs targeting IGFBP-3 alleviate age related erectile dysfunction in the rat.

PURPOSE: We investigated whether injecting shRNA constructs targeting IGFBP-3 in the penis of old rats would improve erectile function. MATERIALS AND METHODS: The most validated IGFBP-3 shRNA plasmid vector (pGPU6/GFP/Neo-shIGFBP-3) was prepared and injected in penile corpus cavernosum tissue. A total of 30 old (age 24 months) male Sprague Dawley® rats were randomly divided into 3 groups, including 10 each that received phosphate buffered saline only (100 µl), pGPU6/GFP/Neo-shNC (100 µg) and the most validated plasmid constructs pGPU6/GFP/Neo-shIGFBP-3 (100 µg). At 4 weeks the erectile response was measured as intracavernous pressure. The percent of smooth muscle in corpus cavernosum tissue was evaluated. Nitric oxide synthase activity and the cGMP concentration in penile tissue were also analyzed. IGFBP-3 was estimated in penile tissue by Western blot, real-time reverse transcriptase-polymerase chain reaction and immunohistochemistry. RESULTS: pGPU6/GFP/Neo-shIGFBP-3 corrected the impaired erectile response in aged rats compared with the response in those injected with phosphate buffered saline and pGPU6/GFP/Neo-shNC (each p <0.01). The percent of cavernous smooth muscle was increased in the pGPU6/GFP/Neo-shIGFBP-3 group. Nitric oxide synthase activity and the cGMP concentration were also significantly increased in rats treated with pGPU6/GFP/Neo-shIGFBP-3. IGFBP-3 shRNA effectively reduced IGFBP-3 mRNA and protein expression in penile corpus cavernosum tissue. CONCLUSIONS: Decreasing IGFBP-3 expression by plasmid expressed shRNA improved erectile function in aged rats. The therapy may modulate smooth muscle integrity and increase the cGMP concentration. This may be a new direction for treating erectile dysfunction in clinical practice.

Identification and functional analysis of the gene ste9 involving in Ebosin biosynthesis from Streptomyces sp. 139.

Ebosin is a novel exopolysaccharide produced by Streptomyces sp. 139 with remarkable antirheumatic arthritis activity in vivo, and its biosynthesis gene cluster (ste) consisting of 27 ORFs has been identified. For functional analysis, one of the ste genes, ste9, was disrupted and then the gene complementation was performed. The resultant mutant Streptomyces sp. 139 (ste9(-)) produced polysaccharides with molecular weights of about 4.153 × 10(5) which is much smaller than that of Ebosin (9.03 × 10(5)). The complemented strain Streptomyces sp. 139 (pKC9c) showed recovery in the molecular weights of EPS produced (8.004 × 10(5)). As the theoretical protein product of ste9 is a chain length determinant (Wzz) homologue by sequence similarity, ste9 was cloned and expressed in E. coli 086:H2 (wzz(-)) for a complementation test. SDS-PAGE analysis showed that E. coli 086:H2 (wzz(-)) (pET30a-ste9) produced a modal chain length lipid polysaccharide (LPS) similar to that of the wild-type E. coli 086:H2. In addition, the expression of ste9 was able to restore the serum resistance of E. coli 086:H2 (wzz(-)) to almost the level of the wild-type strain. These results indicate that the ste9 gene is coding for a chain length determinant which plays an important role in Ebosin biosynthesis.